Table 2.

The Most Frequently Detected (≥20%) Alterations in the Tumor Groups Analyzed by Array-CGH

Alterationa	Chromosomal region	No of cases (%)				P-valueb
		Flanking clone (from pter-qter)	FL prior to transformation	tDLBCL	dnDLBCL	FL vs tDLBCL	tDLBCL vs dnDLBCL
1p loss
Subregion FL	1p35.3–36.11	RP3–398I9//RP3–437I16	8 (53)	5 (17)	3 (10)	0.02	ns
Subregion tDLBCL	1p36.32–36.33	CTB-14E10//RP1–37J18	6 (40)	11 (38)	2 (7)	ns	0.01
Subregion de novo DLBCL	1p36.32–36.12	CTB-14E10//RP11–418J17	0–9 (0–53)	1–11 (3–38)	2–5 (7–17)	ns-0.008–0.0001-nsc	ns-ns-0.01-ns
2p gain
Subregion FL	2p15–16.3	RP11–19A8//RP11–52F10	3 (20)	6–12 (21–41)	1 (3)	ns	ns−0.001
Subregion tDLBCL	2p15–16.1	RP11–260K8//RP11–261A24	3 (20)	12 (41)	1 (3)	ns	0.001
6q loss
Subregion FL	6q23.2–24.1	RP11–557H15//RP11–15H7	3 (20)	7–8 (24–28)	9 (31)	ns	ns
Subregion tDLBCL	6q16.3–16.3	RP11–117M4//RP3–449G2	1 (7)	9 (31)	11–12 (38–41)	ns	ns
Subregion de novo DLBCL	6q16.3–22.1	RP3–449G2//RP3–383B8	0 (0)	7–9 (24–31)	12 (41)	ns-0.02	ns
8q gain
Subregion FL	8q12.2–12.2	RP11–35A5//RP3–491L6	8 (53)	9–10 (31–34)	1 (3)	ns	0.01–0.005
Subregion tDLBCL	8q12.2–12.2	RP11–35A5//RP11–35A5	8 (53)	10 (34)	1 (3)	ns	0.005
13q loss
Subregion FL	13q31.3–32.1	RP11–632L2//RP11–318K19	3 (20)	6 (21)	0–1 (0–3)	ns	0.02–0.05
Subregion tDLBCL	13q21.1–21.31	RP11–516G5//RP11–67L17	1–2 (7–14)	8 (28)	2 (7)	ns	ns
Subregion de novo DLBCL	13q21.32-21.33	RP11–424E21//RP11–393H6	2 (14)	6–7 (21–24)	2 (7)	ns	ns
15q loss
Subregion 1 tDLBCL	15q24.1–24.1	RP11-8P11//RP11–414J4	1 (7)	8 (28)	1 (3)	ns	0.03
Subregion 2 tDLBCL	15q26.1–26.3	RP11–326A19//CTB-154P1	1 (7)	8 (28)	1 (3)	ns	0.03
Subregion de novo DLBCL	15q21.1–21.1	RP11–151N17//RP11–151N17	2 (14)	7 (24)	5 (7)	ns	ns
17q gain
Subregion 1 tDLBCL	17q21.33-21.33	RP11–94C24//RP11–506D12	0 (0)	8 (28)	0 (0)	0.04	0.004
Subregion 2 tDLBCL	17q22–23.1	RP11–19F16//RP11–178C3	0 (0)	8 (28)	0–2 (0–7)	0.04	0.004-ns
18q gain
Subregion FL	18q21.1–21.32	RP11–116K4//RP11–396N11	8 (53)	7–8 (24–28)	10–11 (34–38)	ns	ns
Subregion tDLBCL	18q21.32-21.32	RP11–396N11//RP11–396N11	8 (53)	8 (28)	10 (34)	ns	ns
Subregion de novo DLBCL	18q12.3–21.32	RP11–486C18//RP11–350K6	6–8 (21–28)	6–7 (21–24)	11 (38)	ns-ns-0.04-ns	ns
19p loss
Subregion FL	19p13.3–13.11	CTC-546C11//CTC-260F20	7 (47)	3–4 (10–14)	0 (0)	0.02–0.03	ns
19q loss
Subregion FL	19q13.2–13.43	CTB-186G2//GS1–1129C9	7 (47)	4 (14)	0 (0)	0.03	ns
22q loss
Subregion FL	22q11.21-13.2	XX-p273a17//RP1–85F18	7 (47)	6 (21)	0 (0)	ns	0.02
Subregion tDLBCL	22q11.21-13.2	XX-p273a17//RP1–85F18	7 (47)	6 (21)	0 (0)	ns	0.02
No of tumors			15	29	29

^aSubregions refer to the most commonly occurring alteration defined by FL, tDLBCL, and dnDLBCL, respectively (see Fig. 1); FL, follicular lymphoma; tDLBCL, transformed diffuse large B-cell lymphoma; dnDLBCL, de novo DLBCL; ns, not significant.

^bFishers exact test, significancy is indicated in bold.

^cStatistical analysis of possible outcomes between the two groups.